Remarks

The rejection of Claims 62 and 63 for lack of antecedent basis has been addressed by amendment of clam 62.

Claim 67 has been split into two, i.e., claims 67 and 76, to ensure that they encompass distinct subject mater.

Claims 73 and 74 are rejected on the grounds that it is unclear what kinds of information would meet them. Claim 74 has been clarified and made dependent of claim 51.

Claim 73 has been cancelled and rewritten as new claim 75, which recites specific functional categories. Support for each element of claim 75 is as follows: phosphatidylinositol turn-over (page 4, line 27), calcium mobilization (page 4, lines 27-28), phosphorylation of intracellular protein messengers (page 4, line 28), ion channel activators (page 4, line 6), ion channel blockers (page 4, line 28), transport binding proteins (page 32, line 3), cAMP formation (page 4, line 29), cell envelope and membrane function (page 32, line 17), cell regulatory functions (page 32, line 20), amino acid biosynthesis (page 33, line 7; page 34, Section 6.4.2.2), fatty acid metabolism (page 33, line 8; page 35, Section 6.4.2.4), phospholipid metabolism (page 33, line 8), steroid metabolism (page 33, line 8), glycolysis (page 3, lines 7-8; page 32, Table 1; page 35, Section 6.4.2.3), gene expression (page 33, line 8), neurotransmission inhibitors (page 4, line 30), protein synthesis inhibitors (page 5, line 1), energy metabolism (page 3, lines 7-8; page 36, Section 1; page 33, line 7; page 34, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1), transcription (page 3, line 8; page 36, Section 6.4.2.1)

Atty. Docket No. HESP0010U-US

Serial No: 09/575,377

6.4.2.5), translation (page 3, line 8), G-protein coupled receptor function (Figure 4), or receptor

transduction (Figure 4 and page 3, line 8).

No new matter has been added.

Conclusions

In view of the above amendments and remarks, the application is believed to be in

condition for allowance. Early notice to that effect is earnestly requested. If it is deemed helpful

to the efficient prosecution of the application, the Examiner is invited to contact Applicant's

undersigned representative by telephone.

Respectfully submitted,

/RobertHahl#33,893/

Robert W. Hahl, Ph.D. Reg. No. 33,893

Neifeld IP Law, PC 4813-B Eisenhower Avenue Alexandria, VA 22304

Tel: 703-415-0012 ext 25

Fax: 703-415-0013